Mitabor Disper (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes certain serotonin receptors (5‑HT2, 5‑HT3) while strongly inhibiting H1 histamine receptors. This combined effect enhances noradrenergic and serotonergic signaling, contributing to its antidepressant activity.

The appropriate dose of Mitabor Disper is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their doctor.

To request Mitabor Disper, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors, plus strong H1 antihistamine activity. This profile often results in pronounced sedation and appetite increase, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about these effects.

Mitabor Disper should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

The medication is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Patients should swallow the tablet whole and avoid crushing or chewing unless specifically instructed.

Serious risks include the potential for agranulocytosis or severe neutropenia, hypersensitivity reactions such as Stevens‑Johnson syndrome, seizures, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Prompt medical attention is required if any of these occur.

Mitabor Disper is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with severe hepatic impairment without appropriate medical supervision.